BACKGROUND: The usefulness of dabigatran etexilate for the prevention of stroke in patients with atrial fibrillation (AF) has been reported. OBJECTIVES: In this study the efficacy and safety of dabigatran etexilate for anticoagulation for AF ablation were examined. METHOD: Patients were divided into three groups: Group 1, interrupted warfarin bridged by heparin between pre- and post-ablation; Group 2, continuous warfarin therapy; and Group 3, dabigatran etexilate therapy. Anticoagulation therapy with warfarin or dabigatran etexilate was performed from 30 days before to at least 90 days after AF ablation. Dabigatran etexilate was administered at 110 or 150 mg twice daily, depending on renal function and age. RESULTS: Patients' clinical characteristics, associated disorders, echocardiographic parameters and arrhythmia status were not different among the three groups. Procedural parameters such as procedural time and radiofrequency energy supply were also not different among the three groups. The dabigatran etexilate group and the warfarin groups had no embolic complications (stroke, cerebral transient ischaemic attack, deep venous thrombosis or pulmonary embolism). No pericardial tamponade was observed in the dabigatran etexilate group, while two patients in each of Group 1 (2/194, 1.0 %) and Group 2 (2/203, 0.98 %) developed cardiac tamponade, though the differences were not significant. Pericardial effusion and groin haematoma were observed in one patient each (1/105, 0.9 %) in the dabigatran etexilate group, and the incidences were not different from the warfarin group (Group 1: 4/194, 2.1 % and 2/194, 1.0 %; Group 2: 3/203, 1.5 % and 2/203, 1.0 %, respectively). As a whole, the safety outcomes did not differ among the three groups. CONCLUSION:Dabigatran etexilate is an effective and safe anticoagulation therapy for AF ablation. Thus, dabigatran etexilate appears to be useful as an alternative anticoagulant therapy to warfarin for AF ablation.
RCT Entities:
BACKGROUND: The usefulness of dabigatran etexilate for the prevention of stroke in patients with atrial fibrillation (AF) has been reported. OBJECTIVES: In this study the efficacy and safety of dabigatran etexilate for anticoagulation for AF ablation were examined. METHOD:Patients were divided into three groups: Group 1, interrupted warfarin bridged by heparin between pre- and post-ablation; Group 2, continuous warfarin therapy; and Group 3, dabigatran etexilate therapy. Anticoagulation therapy with warfarin or dabigatran etexilate was performed from 30 days before to at least 90 days after AF ablation. Dabigatran etexilate was administered at 110 or 150 mg twice daily, depending on renal function and age. RESULTS:Patients' clinical characteristics, associated disorders, echocardiographic parameters and arrhythmia status were not different among the three groups. Procedural parameters such as procedural time and radiofrequency energy supply were also not different among the three groups. The dabigatran etexilate group and the warfarin groups had no embolic complications (stroke, cerebral transient ischaemic attack, deep venous thrombosis or pulmonary embolism). No pericardial tamponade was observed in the dabigatran etexilate group, while two patients in each of Group 1 (2/194, 1.0 %) and Group 2 (2/203, 0.98 %) developed cardiac tamponade, though the differences were not significant. Pericardial effusion and groin haematoma were observed in one patient each (1/105, 0.9 %) in the dabigatran etexilate group, and the incidences were not different from the warfarin group (Group 1: 4/194, 2.1 % and 2/194, 1.0 %; Group 2: 3/203, 1.5 % and 2/203, 1.0 %, respectively). As a whole, the safety outcomes did not differ among the three groups. CONCLUSION:Dabigatran etexilate is an effective and safe anticoagulation therapy for AF ablation. Thus, dabigatran etexilate appears to be useful as an alternative anticoagulant therapy to warfarin for AF ablation.
Authors: Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang Journal: Circulation Date: 2006-07-03 Impact factor: 29.690
Authors: L Samuel Wann; Anne B Curtis; Kenneth A Ellenbogen; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy Journal: J Am Coll Cardiol Date: 2011-02-14 Impact factor: 24.094
Authors: Hakan Oral; Aman Chugh; Mehmet Ozaydin; Eric Good; Jackie Fortino; Sundar Sankaran; Scott Reich; Petar Igic; Darryl Elmouchi; David Tschopp; Alan Wimmer; Sujoya Dey; Thomas Crawford; Frank Pelosi; Krit Jongnarangsin; Frank Bogun; Fred Morady Journal: Circulation Date: 2006-08-14 Impact factor: 29.690
Authors: Oussama M Wazni; Salwa Beheiry; Tamer Fahmy; Conor Barrett; Steven Hao; Dimpi Patel; Luigi Di Biase; David O Martin; Mohamed Kanj; Mauricio Arruda; Jennifer Cummings; Robert Schweikert; Walid Saliba; Andrea Natale Journal: Circulation Date: 2007-11-12 Impact factor: 29.690
Authors: Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf Journal: Circulation Date: 2008-10-27 Impact factor: 29.690
Authors: Daniel Scherr; Kavita Sharma; Darshan Dalal; David Spragg; Karuna Chilukuri; Alan Cheng; Jun Dong; Charles A Henrikson; Saman Nazarian; Ronald D Berger; Hugh Calkins; Joseph E Marine Journal: J Cardiovasc Electrophysiol Date: 2009-12
Authors: Pasquale Santangeli; Luigi Di Biase; Javier E Sanchez; Rodney Horton; Andrea Natale Journal: Cardiol Res Pract Date: 2011-04-26 Impact factor: 1.866
Authors: Martin Martinek; Marianne Gwechenberger; Daniel Scherr; Clemens Steinwender; Markus Stühlinger; Helmut Pürerfellner; Franz Xaver Roithinger; Lukas Fiedler Journal: Wien Klin Wochenschr Date: 2018-01-25 Impact factor: 1.704
Authors: Anene Ukaigwe; Pragya Shrestha; Paras Karmacharya; Sarah K Hussain; Soraya Samii; Mario D Gonzalez; Deborah Wolbrette; Gerald V Naccarrelli Journal: J Interv Card Electrophysiol Date: 2016-10-22 Impact factor: 1.900
Authors: Ghada A Bawazeer; Hadeel A Alkofide; Aya A Alsharafi; Nada O Babakr; Arwa M Altorkistani; Tarek S Kashour; Michael Miligkos; Khalid M AlFaleh; Lubna A Al-Ansary Journal: Cochrane Database Syst Rev Date: 2021-10-21
Authors: Giuseppe Santarpia; Salvatore De Rosa; Alberto Polimeni; Salvatore Giampà; Mariella Micieli; Antonio Curcio; Ciro Indolfi Journal: PLoS One Date: 2015-05-14 Impact factor: 3.240
Authors: Anne-Sophie Dincq; Sarah Lessire; Jonathan Douxfils; Jean-Michel Dogné; Maximilien Gourdin; François Mullier Journal: Biomed Res Int Date: 2014-09-03 Impact factor: 3.411